Research programme: cancer therapeutics - Viridis Biotech

Drug Profile

Research programme: cancer therapeutics - Viridis Biotech

Latest Information Update: 10 Dec 2014

Price : $50

At a glance

  • Originator Medical Marijuana Sciences
  • Developer University of Northern Colorado; Viridis Biotech
  • Class Cannabinoids; Cell therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Brain cancer; Pancreatic cancer

Most Recent Events

  • 08 Dec 2014 Medical Marijuana Sciences is now called Viridis Biotech
  • 09 May 2014 Nuvilex and the University of Northern Colorado form a research agreement concerning a Cell-in-a-Box®/cannabinoid combination in USA for Cancer
  • 25 Apr 2014 Preclinical trials in Pancreatic cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top